Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

@article{Guay1999IntrapartumAN,
  title={Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial},
  author={Laura A. Guay and Philippa Musoke and Thomas Fleming and Danstan S Bagenda and Melissa Allen and Clemensia Nakabiito and Joseph Sherman and Paul M. Bakaki and Constance Ducar and Martina Deseyve and Lynda Marie Emel and Mark Mirochnick and Mary Glenn Fowler and Lynne M Mofenson and Paolo G. Miotti and Kevin Dransfield and Dorothy H. Bray and Francis A. Mmiro and J Brooks Jackson},
  journal={The Lancet},
  year={1999},
  volume={354},
  pages={795-802}
}
BACKGROUND The AIDS Clinical Trials Group protocol 076 zidovudine prophylaxis regimen for HIV-1-infected pregnant women and their babies has been associated with a significant decrease in vertical HIV-1 transmission in non-breastfeeding women in developed countries. We compared the safety and efficacy of short-course nevirapine or zidovudine during labour and the first week of life. METHODS From November, 1997, to April, 1999, we enrolled 626 HIV-1-infected pregnant women at Mulago Hospital… Expand

Paper Mentions

Interventional Clinical Trial
The purpose of this study is to see if nevirapine (NVP) or zidovudine (AZT), given to mothers during labor and delivery and to their babies during the first week of life, can reduce the… Expand
ConditionsHIV Infections
InterventionDrug
Observational Clinical Trial
This study will look at how well the OraQuick HIV 1/2 Antibody rapid test works and how women accept being tested for HIV late in pregnancy and during labor. For women with positive… Expand
ConditionsHIV Infections
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial
TLDR
Intrapartum/ne ononatal nevirapine significantly lowered HIV-1 transmission risk in a breastfeeding population in Uganda compared with a short intrapartu/neonatal zidovudine regimen. Expand
Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial
TLDR
Postexposure prophylaxis can offer protection against HIV infection to babies of women who missed opportunities to be counselled and tested before or during pregnancy. Expand
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
TLDR
A single dose of nevirapine to the mother, with or without a dose ofNevirapin to the infant, added to oral zidovudine prophylaxis starting at 28 weeks' gestation, is highly effective in reducing mother-to-child transmission of HIV. Expand
Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.
TLDR
The frequency of mother-to-child HIV transmission at 6 to 8 weeks in the authors' 2 study groups was comparable with that observed for other perinatal HIV intervention studies among breastfeeding women in Africa. Expand
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
TLDR
The efficacy and safety of short-course ARV regimens in reducing MTCT rates in developing countries is confirmed and the total number of infants infected by 8 weeks was 1307. Expand
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
TLDR
Breastfeeding with zidovudine prophylaxis was not as effective as formula feeding in preventing postnatal HIV transmission, but was associated with a lower mortality rate at 7 months, and both strategies had comparable HIV-free survival at 18 months. Expand
Safety and Efficacy of HIV Hyperimmune Globulin for Prevention of Mother-to-Child HIV Transmission in HIV-1–Infected Pregnant Women and Their Infants in Kampala, Uganda (HIVIGLOB/NVP STUDY)
TLDR
Giving mother–infant pairs an infusion of peripartum HIV hyperimmune globulin in addition tosdNVP for preventing maternal-to-child transmission was as safe as sdNVP alone but was no more effective than sdN VP alone in preventing HIV transmission. Expand
Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.
TLDR
Risk of perinatal HIV transmission was low and no benefit from additional intrapartum/newborn nevirapine was demonstrated when women received prenatal care and antenatal ART, and elective cesarean section was made available. Expand
A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers
TLDR
A single-dose of NVP given to infants offers protection against HIV-1 infection and should be a strategy used in infants of mothers with untreated HIV infection. Expand
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana
TLDR
In the setting of maternal zidvudine and infant zidovudine plus single- dose nevirapine, infant HIV infection rates were similar whether women received single-dose nevirabine or placebo, and this strategy avoids the potential for maternal nevirAPine resistance. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial
TLDR
A short course of twice-daily oral zidovudine was safe and well tolerated and, in the absence of breastfeeding, can lessen the risk for mother-to-child HIV-1 transmission by half. Expand
Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial
TLDR
Short-course oral zidovudine was safe, well tolerated, and decreased mother-to-child transmission of HIV-1 at age 3 months, and substantial efforts will be needed to ensure successful widespread implementation of such a regimen. Expand
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
TLDR
In pregnant women with mildly symptomatic HIV disease and no prior treatment with antiretroviral drugs during the pregnancy, a regimen consisting of zidovudine given ante partum and intra partum to the mother and to the newborn for six weeks reduced the risk of maternal-infant HIV transmission by approximately two thirds. Expand
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).
TLDR
The administration of a single dose of nevirapine to women during labor and to their newborns at 72 h was well tolerated and showed potent antiretroviral activity in the women at 1 week after dosing without rebound above baseline 6 weeks after a single doses. Expand
Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa
TLDR
The cost effectiveness of HIVNET 012 was robust under a wide range of parameters in the sensitivity analysis, and in lower seroprevalence areas, when multidose regimens are not cost effective, nevirapine therapy could have a major public-health impact at a reasonable cost. Expand
6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial
TLDR
A short course of oral zidovudine given during the peripartum period is well accepted and well tolerated, and provides a 38% reduction in early vertical transmission of HIV-1 infection despite breastfeeding. Expand
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
TLDR
To prevent HIV-1 transmission, initiating maternal treatment with zidovudine is recommended regardless of the plasma level of HIV- 1 RNA or the CD4+ count, and the reduction in viral RNA from base line to delivery was not significantly associated with the risk of transmission. Expand
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.
The safety, toxicity, and pharmacokinetics of intrapartum and early newborn nevirapine were evaluated in 17 human immunodeficiency virus type 1-infected women in labor and their newborns. No adverseExpand
International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection
TLDR
Risk of late postnatal transmission is consistently shown to be substantial for breastfed children born to HIV-1-positive mothers, and should be balanced against the effect of early weaning on infant mortality and morbidity and maternal fertility. Expand
Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire.
TLDR
The results support earlier studies indicating that most transmission occurs during labor and delivery or in the early postpartum period and that the risk of HIV transmission through breast-feeding during the post partum period is substantial. Expand
...
1
2
...